Program
Mesenchymal stem cells(HucMSCs)
Its studies are mostly in Heart Failure, led by China Resources Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Resources Pharmaceutical Group | 11 open or running | phase 2since Nov 20, 2025 | Nov 20, 2025 | Dec 31, 2026phase 2 · NCT07265349 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2025First study: phase 2 study in Coronary Artery Bypass Grafting (CABG)First studyNCT07265349 · 51 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Coronary Artery Bypass Grafting (CABG)NCT07265349
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07265349Coronary Artery Bypass Grafting (CABG) · China | 2 | Recruiting | Dec 31, 2026 | 51 |
How it is read
Names in the registry
- “Mesenchymal stem cells(HucMSCs)”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.